---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-014285"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:37:02.797255+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma gets FDA orphan drug designation for efzofitimod in systemic sclerosis

## Summary
- FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
- Efzofitimod is aTyr's lead therapeutic candidate; orphan status provides development incentives and market exclusivity potential.
- Systemic sclerosis is a rare autoimmune disease; designation underscores unmet medical need.

## SEC filing metadata
- accession: 0001564590-22-014285
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459022014285/0001564590-22-014285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459022014285/life-8k_20220412.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-014285
- JSON: https://secwatch.observer/filing/0001564590-22-014285.json
- Plain text: https://secwatch.observer/filing/0001564590-22-014285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.